Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Cambiar Investors LLC

Cambiar Investors LLC lowered its position in Exelixis, Inc. (NASDAQ:EXEL) by 7.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 86,292 shares of the biotechnology company’s stock after selling 7,420 shares during the quarter. Cambiar Investors LLC’s holdings in Exelixis were worth $2,874,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in EXEL. V Square Quantitative Management LLC acquired a new position in shares of Exelixis during the third quarter worth about $30,000. USA Financial Formulas acquired a new position in shares of Exelixis during the fourth quarter worth about $32,000. Brooklyn Investment Group acquired a new position in shares of Exelixis during the third quarter worth about $42,000. UMB Bank n.a. lifted its stake in shares of Exelixis by 68.4% during the fourth quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 553 shares in the last quarter. Finally, Capital Performance Advisors LLP acquired a new position in shares of Exelixis during the third quarter worth about $61,000. Institutional investors and hedge funds own 85.27% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Brookline Capital Management assumed coverage on Exelixis in a research report on Monday, December 23rd. They set a “buy” rating on the stock. Stifel Nicolaus lifted their target price on Exelixis from $26.00 to $30.00 and gave the stock a “hold” rating in a research report on Wednesday, October 16th. Piper Sandler boosted their price objective on Exelixis from $36.00 to $37.00 and gave the company an “overweight” rating in a report on Monday, January 13th. UBS Group boosted their price objective on Exelixis from $30.00 to $34.00 and gave the company a “neutral” rating in a report on Tuesday, January 28th. Finally, Stephens reissued an “equal weight” rating and issued a $29.00 price objective on shares of Exelixis in a report on Monday, January 27th. One analyst has rated the stock with a sell rating, seven have given a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Exelixis currently has an average rating of “Moderate Buy” and a consensus price target of $36.06.

Exelixis Trading Up 0.1 %

Shares of NASDAQ EXEL opened at $33.50 on Tuesday. The stock has a 50 day simple moving average of $34.35 and a 200-day simple moving average of $30.64. The company has a market cap of $9.57 billion, a PE ratio of 21.47, a P/E/G ratio of 0.63 and a beta of 0.53. Exelixis, Inc. has a 12-month low of $20.01 and a 12-month high of $37.59.

Insider Transactions at Exelixis

In other Exelixis news, EVP Jeffrey Hessekiel sold 60,000 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $36.67, for a total value of $2,200,200.00. Following the completion of the sale, the executive vice president now directly owns 486,059 shares in the company, valued at $17,823,783.53. This represents a 10.99 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Patrick J. Haley sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $35.27, for a total value of $352,700.00. Following the completion of the sale, the executive vice president now owns 278,665 shares of the company’s stock, valued at $9,828,514.55. This trade represents a 3.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 111,588 shares of company stock worth $3,981,864. Company insiders own 2.85% of the company’s stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.